Background: Erythroplasia of Queyrat (EQ) is a rare squamous cell carcinoma in situ, usually occurring on the glans penis, the prepuce, or the urethral meatus. Therapy is mandatory because it can progress to invasive carcinoma in up to 30% of cases. Treatment options include 5-fluorouracil, curettage, cryotherapy, radiotherapy, laser, partial or total penectomy, and microsurgery, as also with imiquimod and photodynamic therapies. Methods: Between 2015 to 2018 we treated five patients, with histologically confirmed EQ, with ingenol mebutate (IM) 0.015% gel applied for 3 days consecutively. Results: Three patients showed complete response at one year follow up. Two patients showed partial response after two months, so they received a second course of therapy with IM. At one-year follow-up, one of them showed complete response, the other partial response. Conclusions: Our experience demonstrated that IM may be considered as an effective and safe treatment option in EQ. IM offers various advantages such as easy and fast application, rapid complete remission, better compliance, few side effects and excellent cosmetical results. The authors call for further exploitation in bigger trials.

Ingenol mebutate therapy in erythroplasia of Queyrat: a new approach / Proietti, Ilaria; Michelini, Simone; Skroza, Nevena; Bernardini, Nicoletta; Tolino, Ersilia; Anzalone, Alessia; Colapietra, Daniela; Mambrin, Alessandra; DI Fraia, Marco; Marchesiello, Anna; Balduzzi, Veronica; Porta, Natale; Petrozza, Vincenzo; Potenza, Concetta. - In: ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY. - ISSN 2784-8671. - 156:3(2021), pp. 388-391. [10.23736/S2784-8671.19.06371-5]

Ingenol mebutate therapy in erythroplasia of Queyrat: a new approach

Proietti, Ilaria;Michelini, Simone;Skroza, Nevena;Bernardini, Nicoletta;Tolino, Ersilia;Anzalone, Alessia;Colapietra, Daniela;Mambrin, Alessandra;DI Fraia, Marco;Marchesiello, Anna;Balduzzi, Veronica;Porta, Natale;Petrozza, Vincenzo;Potenza, Concetta
2021

Abstract

Background: Erythroplasia of Queyrat (EQ) is a rare squamous cell carcinoma in situ, usually occurring on the glans penis, the prepuce, or the urethral meatus. Therapy is mandatory because it can progress to invasive carcinoma in up to 30% of cases. Treatment options include 5-fluorouracil, curettage, cryotherapy, radiotherapy, laser, partial or total penectomy, and microsurgery, as also with imiquimod and photodynamic therapies. Methods: Between 2015 to 2018 we treated five patients, with histologically confirmed EQ, with ingenol mebutate (IM) 0.015% gel applied for 3 days consecutively. Results: Three patients showed complete response at one year follow up. Two patients showed partial response after two months, so they received a second course of therapy with IM. At one-year follow-up, one of them showed complete response, the other partial response. Conclusions: Our experience demonstrated that IM may be considered as an effective and safe treatment option in EQ. IM offers various advantages such as easy and fast application, rapid complete remission, better compliance, few side effects and excellent cosmetical results. The authors call for further exploitation in bigger trials.
2021
ingenol mebutate; Therapeutics; Penis; Erythroplasia
01 Pubblicazione su rivista::01a Articolo in rivista
Ingenol mebutate therapy in erythroplasia of Queyrat: a new approach / Proietti, Ilaria; Michelini, Simone; Skroza, Nevena; Bernardini, Nicoletta; Tolino, Ersilia; Anzalone, Alessia; Colapietra, Daniela; Mambrin, Alessandra; DI Fraia, Marco; Marchesiello, Anna; Balduzzi, Veronica; Porta, Natale; Petrozza, Vincenzo; Potenza, Concetta. - In: ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY. - ISSN 2784-8671. - 156:3(2021), pp. 388-391. [10.23736/S2784-8671.19.06371-5]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1673038
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact